Pharma channel feed – Endpoints News

Pharma channel feed

Scoop: Pfizer once again takes out the budget ax, lopping off 150 R&D staffers and 5 preclinical biosimilar drugs

7 years ago

EMA to lose 25% of staff as hard Brexit approaches

7 years ago

Is JPM worth it? As the buzzy conference dies down, debate on its value rumbles on

7 years ago

FDA staff largely unfazed by CV signal in Amgen osteoporosis drug trials

7 years ago

J&J hikes US prices for a basket of drugs, including certain top-sellers — Reuters

7 years ago

As JPMorgan madness subsides, Democrats will unveil a legislative package to address drug price hikes

7 years ago

The first patient has been treated under the controversial 'right to try' law

7 years ago

Denali broadens tech to infiltrate the blood-brain barrier with Sirion deal

7 years ago

Anti-aging startup Unity dives into eye diseases as partnership with Ascentage bears fruit

7 years ago

‘It’s us against the world’: And George Yancopoulos wants you to know they are beating the world — big time

7 years ago

Bluebird endorses plan for installment-based payments for costly gene therapy

7 years ago

Billed as potential blockbuster, Novartis' sickle cell drug scores FDA's breakthrough therapy status

7 years ago

FDA has about one month of user fee funds left, Gottlieb warns

7 years ago

TCR deal spree intensifies as Roche commits up to $2B in Adaptive Biotech to develop personalized cancer drugs

7 years ago

Shifting focus, Sanofi agrees to pay Regeneron $462M for an early wrap of their big I/O alliance

7 years ago

Remember that mega-blockbuster valuation AbbVie assigned to Rova-T? It’s starting to vanish — quietly

7 years ago

Joining forces with Skyhawk, C4 Therapeutics, Biogen buys more shots on goal on SMA, Alzheimer's

7 years ago

Daiichi Sankyo lines up a $900M deal for rights to a cholesterol drug looking to disrupt a blockbuster market

7 years ago

Sanofi sharpens focus on mRNA for cancer with equity investment in Germany's BioNTech

7 years ago

Jazz triggers Codiak’s first exosome alliance with a $76M ante and up to $1B-plus in milestones

7 years ago

After blueprinting R&D hub, AbbVie dishes out $105M for CD39 pact with Tizona's new CEO from Roche

7 years ago

Takeda builds arsenal for immuno-oncology research, creates cell therapy group

7 years ago

Gene silencing company NeuBase Therapeutics to reverse merge its way onto Nasdaq via troubled microcap Ohr

7 years ago

Bristol-Myers inks a $74B deal to buy out Celgene, expects $15B a year from late-stage pipeline

7 years ago

First page Previous page 279 280 281282283 284 285 Next page Last page